Notably, NTN4 significantly correlates with clinical outcome of breast cancer patients, including overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS) (Fig. 4A–C, OS: HR (95% CI) 0.68 (0.52–0.89), P = 0.0047; RFS: HR (95% CI) 0.7 (0.67–0.82), P = 3.9e−06; DMFS: HR (95% CI) 0.68 (0.52–0.89), P = 0.0046, respectively). This evidence concerns the gene NTN4 and breast carcinoma.